The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | Subgroup and toxicity insights from AMIGO-1 in in EGFRm NSCLC
William William Jr., MD, Oncoclínicas, São Paulo, Brazil, shares insights into findings from the AMIGO-1 trial of pemetrexed, amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer (NSCLC). The number of pemetrexed cycles was capped, which kept toxicities manageable, and particular progression-free survival benefit from the treatment intensification was seen in patients with TP53 co-mutations who typically have a poorer prognosis. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
